On Dec. 30, 2011, Pfizer announced that the U.S. Food and Drug Administration (FDA) had granted approval of the Company’s pneumococcal conjugate vaccine Prevnar 13^® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM₁₉₇ Protein]) as a single dose for use in adults.

Prevnar 13 was indicated for adults 50 years of age and older for active immunization for the prevention of pneumonia and invasive disease caused by the 13 Streptococcus pneumoniae (S. pneumoniae) serotypes contained in the vaccine. In this population, there were estimated to be hundreds of thousands of S. pneumoniae infections per year, including more than 440,000 cases of pneumococcal pneumonia, accounting for an estimated 200,000 emergency department visits and 300,000 hospitalizations.